A Phase I, Single Centre, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Assess the Safety, Tolerability and Pharmacokinetics of Oral AZD2423 Solution After Administration of Multiple Ascending Doses for 12 Days in Young and Elderly Healthy Japanese Volunteers.
Phase of Trial: Phase I
Latest Information Update: 11 Apr 2011
At a glance
- Drugs AZD 2423 (Primary)
- Indications Chronic obstructive pulmonary disease; Neuropathic pain
- Focus Adverse reactions
- 08 Dec 2010 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
- 15 Nov 2010 New trial record